What is the 13F Pro Quality Score for INO?

13F Pro ranks INOVIO PHARMACEUTICALS, INC. (INO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INO's current score at https://13fpro.ai/research/INO (free sign-up required for the full ranking).

Which hedge funds own the most INO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of INO include FMR, JANUS HENDERSON GROUP PLC, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/INO as soon as new 13F filings post.

Where does 13F Pro source INO data?

All INOVIO PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. INOVIO PHARMACEUTICALS, INC. files with the SEC under CIK 1055726. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INO in?

INOVIO PHARMACEUTICALS, INC. (INO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INO research updated on 13F Pro?

INO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

INOVIO PHARMACEUTICALS, INC.(INO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1055726 INO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

INO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for INOVIO PHARMACEUTICALS, INC. (INO), a Healthcare sector company. INO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), INOVIO PHARMACEUTICALS, INC. reports net income of $-19.7M, free cash flow of $-21.6M. Top institutional holders of INO by reported 13-F value include FMR, JANUS HENDERSON GROUP PLC, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. INO trades on the Nasdaq exchange and files with the SEC under CIK 1055726. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INOVIO PHARMACEUTICALS, INC. directly from SEC EDGAR. INOVIO PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 2 and 24 since 2024, currently 6.8 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-19.7M

Free Cash Flow

Q1 2026

$-21.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-70.0% YoY

$65.3KFY 2025

FY21 $1.8MFY22 $10.3MFY24 $217.8KFY25 $65.3K

Net Income

+20.7% YoY

$-85.0MFY 2025

FY21 $-303.7MFY22 $-279.8MFY24 $-107.3MFY25 $-85.0M

Operating Income

+22.8% YoY

$-86.8MFY 2025

FY21 $-301.2MFY22 $-267.6MFY24 $-112.4MFY25 $-86.8M

EPS (Diluted)

+54.2% YoY

$-1.81FY 2025

FY21 $-17.45FY22 $-14.07FY24 $-3.95FY25 $-1.81

Total Assets

-34.4% YoY

$74.3MFY 2025

FY21 $495.9MFY22 $348.5MFY24 $113.2MFY25 $74.3M

Op. Cash Flow

+14.8% YoY

$-88.6MFY 2025

FY21 $-215.7MFY22 $-216.2MFY24 $-104.1MFY25 $-88.6M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$65.3K -70.0%	$217.8K -97.9%	$10.3M +478.2%	$1.8M -76.1%	$7.4M +80.2%	$4.1M
Net Income	$-85.0M +20.7%	$-107.3M +61.7%	$-279.8M +7.9%	$-303.7M -82.5%	$-166.4M -39.4%	$-119.4M
Operating Income	$-86.8M +22.8%	$-112.4M +58.0%	$-267.6M +11.2%	$-301.2M -142.8%	$-124.1M -11.7%	$-111.1M
EPS (Diluted)	$-1.81 +54.2%	$-3.95 +71.9%	$-14.07 +19.4%	$-17.45 -1530.8%	$-1.07 +11.6%	$-1.21
Total Assets	$74.3M -34.4%	$113.2M -67.5%	$348.5M -29.7%	$495.9M -8.1%	$539.8M +275.0%	$144.0M
Operating Cash Flow	$-88.6M +14.8%	$-104.1M +51.9%	$-216.2M -0.2%	$-215.7M -21.2%	$-178.0M -81.9%	$-97.9M

AI Insight: INO Financial Trends

Inovio remains pre-revenue with accelerating cash burn and equity near zero despite Q4 2025 net income inflection.

• Revenue remains at $0M across all eight quarters. Operating cash outflow persisted at $19–$28M quarterly.

• Q4 2025 net income swung to +$4M, but Q1 2026 reversed to –$20M loss. One-quarter positive not sustained.

• Equity eroded from $97M (Q2 2024) to $6M (Q1 2026). Company briefly dipped to –$8M equity in Q3 2025.

⚠ Cash burn remains $19–$28M per quarter with zero revenue. Runway appears extremely limited at current equity of $6M.

⚠ Q4 2025 profit appears anomalous; lack of revenue and continued OpCF losses suggest non-cash or one-time items.

AI Insight: INO Ratio Trends

INO swung to positive ROE of 62.5% in Q4 2025 after four consecutive quarters of severe losses, signaling a potential inflection toward profitability.

• ROE and ROA both turned sharply positive in Q4 2025 (62.5% and 20.3%, respectively) after consistent deep negative returns in Q2–Q1 2025.

• ROA improved 110.8 percentage points from Q1 2025's -90.3% to Q4 2025's 20.3%, marking the first positive return on assets in 3 quarters.

⚠ Q1 2026 data is missing; cannot confirm whether Q4 2025 profitability improvement is sustained or a one-quarter anomaly.

⚠ All margin metrics (OpMargin, NPM) remain unreported across the entire period, limiting visibility into operational leverage.

Get alerted when INO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for INOVIO PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INO

FMR LLC
$16.3M9,339,614 sh
JANUS HENDERSON GROUP PLC
$5.8M3,308,406 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.0M2,901,208 sh
Boxer Capital Management, LLC
$4.1M2,370,122 sh
D. E. Shaw & Co., Inc.
$3.9M2,212,819 sh
ADAR1 Capital Management, LLC
$2.6M1,470,108 sh
MILLENNIUM MANAGEMENT LLC
$2.5M1,410,845 sh
Eversept Partners, LP
$1.8M1,035,360 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$1.4M804,958 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.4M801,504 sh

Fund	Value	Shares
FMR LLC	$16.3M	9,339,614
JANUS HENDERSON GROUP PLC	$5.8M	3,308,406
VANGUARD CAPITAL MANAGEMENT LLC	$5.0M	2,901,208
Boxer Capital Management, LLC	$4.1M	2,370,122
D. E. Shaw & Co., Inc.	$3.9M	2,212,819
ADAR1 Capital Management, LLC	$2.6M	1,470,108
MILLENNIUM MANAGEMENT LLC	$2.5M	1,410,845
Eversept Partners, LP	$1.8M	1,035,360
ADAGE CAPITAL PARTNERS GP, L.L.C.	$1.4M	804,958
GEODE CAPITAL MANAGEMENT, LLC	$1.4M	801,504

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INO on your watchlist

Track score changes the day INOVIO PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INO a good stock to buy?

13F Pro's AI-powered analysis of INOVIO PHARMACEUTICALS, INC. (INO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INO are available on the INO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own INO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INOVIO PHARMACEUTICALS, INC.'s investment landscape.